• Profile
Close

The impact of empagliflozin on obstructive sleep apnea, cardiovascular, and renal outcomes: An exploratory analysis of the EMPA-REG OUTCOME Trial

Diabetes Care Oct 07, 2020

Neeland IJ, Eliasson B, Kasai T, et al. - In the EMPA-REG OUTCOME trial, researchers sought to investigate the effects of empagliflozin on the incidence of obstructive sleep apnea (OSA) and its impacts on metabolic, cardiovascular (CV), and renal outcomes among participants with or without OSA. In addition to standard of care, participants with diabetes and CV disease were randomized to empagliflozin (10 and 25 mg) or placebo daily. In 391 of 7,020 (5.6%) participants at baseline, OSA was reported. In EMPA-REG OUTCOME, OSA participants had greater comorbidity and higher CV and renal events frequency. Empagliflozin, independent of preexisting OSA, has had positive effects on risk factors and CV and renal outcomes and may also decrease the risk for new-onset OSA.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay